These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30651121)

  • 1. Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis.
    Wervers K; Luime JJ; Tchetverikov I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Vis M;
    Arthritis Res Ther; 2019 Jan; 21(1):25. PubMed ID: 30651121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of disease activity measures in early psoriatic arthritis in usual care.
    Wervers K; Luime JJ; Tchetverikov I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Vis M;
    Rheumatology (Oxford); 2019 Dec; 58(12):2251-2259. PubMed ID: 31211399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
    Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
    Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
    Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity.
    Perruccio AV; Got M; Li S; Ye Y; Gladman DD; Chandran V
    J Rheumatol; 2020 Mar; 47(3):362-368. PubMed ID: 31203221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.
    Aletaha D; Alasti F; Smolen JS
    Ann Rheum Dis; 2017 Feb; 76(2):418-421. PubMed ID: 27457512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era.
    Haugeberg G; Michelsen B; Kavanaugh A
    RMD Open; 2020 May; 6(1):. PubMed ID: 32409518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
    van der Heijde D; Kavanaugh A; Gladman DD; Antoni C; Krueger GG; Guzzo C; Zhou B; Dooley LT; de Vlam K; Geusens P; Birbara C; Halter D; Beutler A
    Arthritis Rheum; 2007 Aug; 56(8):2698-707. PubMed ID: 17665424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
    Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
    Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis.
    Geijer M; Lindqvist U; Husmark T; Alenius GM; Larsson PT; Teleman A; Theander E
    J Rheumatol; 2015 Nov; 42(11):2110-7. PubMed ID: 26472410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.
    Coates LC; Helliwell PS
    Arthritis Care Res (Hoboken); 2010 Jul; 62(7):965-9. PubMed ID: 20589696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.
    Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
    J Rheumatol; 2017 Aug; 44(8):1151-1158. PubMed ID: 28620063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis.
    Snoeck Henkemans SVJ; de Jong PHP; Luime JJ; Kok MR; Tchetverikov I; Kasiem FR; Welby S; Prickett AR; van der Helm-van Mil AHM; Vis M;
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls.
    Michelsen B; Uhlig T; Sexton J; van der Heijde D; Hammer HB; Kristianslund EK; Wierød A; Bakland G; Rødevand E; Krøll F; Loge JH; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2018 Sep; 77(9):1290-1294. PubMed ID: 29875096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis.
    Allard A; Antony A; Shaddick G; Jadon DR; Cavill C; Robinson G; Korendowych E; McHugh N; Tillett W
    Rheumatology (Oxford); 2019 Feb; 58(2):269-273. PubMed ID: 30247726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
    Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J
    Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.